SCHEMBL5525359

SCHEMBL5525359

N#CCNC(=O)C(CNC(=O)c1cccc(Oc2ccccc2)c1)SCc1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC8 Q9BY41 1/20 0.46
LMNA P02545 2/20 0.46
ALDH1A1 P00352 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
CTSL P07711 9/20 0.45
CTSS P25774 5/20 0.45
CTSK P43235 4/20 0.45
CTSB P07858 5/20 0.44
CTSV O60911 2/20 0.44
PPARG P37231 1/20 0.42
PPARD Q03181 1/20 0.42
PPARA Q07869 1/20 0.42
RAB9A P51151 1/20 0.42
NPC1 O15118 1/20 0.42
HTT P42858 1/20 0.42
KMT2A Q03164 1/20 0.42
CHRM3 P20309 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5522695 0.92 CTSL (0.53) LMNASMN1; SMN2CTSLRAB9ANPC1
SCHEMBL5524114 0.88 CTSL (0.56) LMNASMN1; SMN2CTSLCTSSCTSK
SCHEMBL5527530 0.87 CTSL (0.46) CTSLCTSSCTSKCTSBCTSV
SCHEMBL5528266 0.87 CTSL (0.50) CTSLCTSSCTSKCTSBCTSV
SCHEMBL5528544 0.87 CTSL (0.46) CTSLCTSSCTSKCTSBCTSV
SCHEMBL5527647 0.86 CTSL (0.55) CTSLCTSSCTSKCTSBCTSV
SCHEMBL5526326 0.86 CTSL (0.46) CTSLCTSSCTSKCTSBCTSV
SCHEMBL6872552 0.85 CTSB (0.47) HDAC8ALDH1A1CTSLCTSSCTSK
SCHEMBL5526533 0.85 CTSS (0.51) HDAC8SMN1; SMN2CTSLCTSSCTSK
SCHEMBL6876674 0.84 LMNA (0.47) LMNAALDH1A1CTSLCTSSCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2007-01-18 US disclosed
US-20040147745-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2004-07-29 US disclosed
EP-1178958-B1 N-CYANOMETHYL AMIDES AS PROTEASE INHIBITORS AXYS PHARM INC (US) 2004-02-18 EP disclosed
US-20030096796-A1 Novel compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. (US) 2003-05-22 US disclosed
US-6455502-B1 Compounds and compositions as protease inhibitors AXYS PHARMACEUTICALS, INC. 2002-09-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030096796-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 HDAC8 571/4885LMNA 1379/4885ALDH1A1 4049/4885
US-20040147745-A1 Novel compounds and compositions as protease inhibitors CTRL, SERPINB1, CPN1 HDAC8 571/4885LMNA 1379/4885ALDH1A1 4049/4885
US-20070015755-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS CTRL, SERPINB1, CPN1 HDAC8 571/4885LMNA 1379/4885ALDH1A1 4049/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.